Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia.
Latest Information Update: 05 Aug 2020
At a glance
- Drugs Irinotecan (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Therapeutic Use
- 30 Jul 2012 Additional lead trial investigator (Hecht JR) and drug company added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual end date added to 1 Jan 2005 as reported by ClinicalTrials.gov.